Peter G. Steinherz - Concepedia

Author

Peter G. Steinherz

Memorial Sloan Kettering Cancer Center ORCID

Also Known As

Jae Hung Shieh, P G Steinherz, P Steinherz, P. G. Steinherz, P. Steinherz, P.G. Steinherz, PETER G. STEINHERZ, PETER STEINHERZ, Peter G Steinherz, Peter G. Steinherz

215

Publications

13K

Citations

H-Index

138

Concepts

All Affiliations

Memorial Sloan Kettering Cancer Center University of Southern California Children's Oncology Group Cornell University Parker Hughes Cancer Center

About

Peter G. Steinherz is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, hematology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	33	51	3.3K
2	Health Sciences	18	19	1.4K
3	Education	2	2	115
4	Public Health	1	1	18
5	Allergy	1	1	231

Peter G. Steinherz

127

Publications

12.1K

Citations

H-Index

Page 1

	Year	Citations
CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia Renier J. Brentjens, Marco L. Davila, Isabelle Rivière, Science Translational Medicine	2013	2.1K
United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia Steven L. Soignet, Stanley R. Frankel, Dan Douer, Journal of Clinical Oncology	2001	822
Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group Nita L. Seibel, Peter G. Steinherz, Harland N. Sather, Blood	2007	308
Phase II Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia Sima Jeha, Paul S. Gaynon, Bassem I. Razzouk, Journal of Clinical Oncology	2006	304
Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL Kevin J. Curran, Steven Margossian, Nancy A. Kernan, Blood Cell TherapyMixed-phenotype Acute LeukemiaImmunologyImmunotherapeuticsT Cells	2019	272
PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study Alison J. Moskowitz, Heiko Schöder, Joachim Yahalom, The Lancet Oncology Lymphoid NeoplasiaRefractory HodgkinAugmented IfosamideBrentuximab VedotinMedicine	2015	263
Myelodysplastic and Myeloproliferative Disorders of Childhood: A Study of 167 Patients Sandra Luna‐Fineman, Kevin Shannon, Susan K. Atwater, Blood	1999	232
Asparaginase Antibody and Asparaginase Activity in Children With Higher-Risk Acute Lymphoblastic Leukemia Eduard H. Panosyan, Nita L. Seibel, Sagrario Martín‐Aragón, Journal of Pediatric Hematology/Oncology Asparaginase ActivityImmunohematologyAnti-asparaginase AntibodyAllergyAb Titer	2004	231
Hypodiploidy with less than 45 chromosomes confers adverse risk in childhood acute lymphoblastic leukemia: a report from the children's cancer group. Nyla A. Heerema, James B. Nachman, Harland N. Sather, PubMed	1999	211
Neuropsychologic effects of cranial irradiation, intrathecal methotrexate, and systemic methotrexate in childhood cancer. Robert W. Butler, James M. Hill, Peter G. Steinherz, Journal of Clinical Oncology	1994	192

Page 1